An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

Trial Profile

An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms X-TRA
  • Sponsors Bayer
  • Most Recent Events

    • 02 Apr 2015 Study protocol published in American Heart Journal.
    • 20 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
    • 13 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top